Australia's most trusted
source of pharma news
Friday, 17 April 2026
Posted 17 April 2026 AM
A new listing on the PBS will allow people with a rare form of lung cancer treatment that is more personalised to their specific cancer.
BMS' next-generation ROS1 tyrosine kinase inhibitor, Augtyro, was funded this month for the treatment pf Stage IIIB or Stage IV ROS1-positive non-small cell lung cancer (NSCLC). It competes with Roche's Rozlytrek.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.